Erudio Healtherudio.com
Indication
Myelodysplastic syndromes trials: what clinicians said in public
No HCP commentary report on a trial in myelodysplastic syndromes yet. Erudio has found public clinician commentary on 15 clinical trials in myelodysplastic syndromes, including BEXMAB, SELECT-MDS-1, STIMULUS-MDS1 and STIMULUS-MDS2. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| BEXMAB NCT05428969 · Faron Pharmaceuticals Ltd DeepView → | myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia | Phase 1/Phase 2 | Deep | View | |||
| STIMULUS-MDS1 NCT03946670 · Novartis Pharmaceuticals DeepView → | previously untreated higher-risk myelodysplastic syndromes | Phase 2 | Deep | View | |||
| STIMULUS-MDS2 NCT04266301 · Novartis Pharmaceuticals StandardView → | higher risk MDS and CMML-2 | Phase 3 | Standard | View | |||
| SELECT-MDS-1 NCT04797780 · Syros Pharmaceuticals StandardView → | newly diagnosed RARA-positive higher-risk myelodysplastic syndromes | Phase 3 | Standard | View | |||
| TELESTO NCT00940602 · Novartis Pharmaceuticals FocusedView → | transfusion-dependent low- to intermediate-1-risk myelodysplastic syndromes | Phase 2 | Focused | View | |||
| OPTIMIZE NCT06001385 · Center for International Blood and Marrow Transplant Research FocusedView → | hematologic malignancies receiving HLA-mismatched unrelated donor transplantation | Phase 2 | Focused | View | |||
| NCT02598661 NCT02598661 · Geron Corporation FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| COMMANDS NCT03682536 · Celgene FocusedView → | ESA-naive, transfusion-dependent, lower-risk myelodysplastic syndromes | Phase 3 | Focused | View | |||
| NCT04849910 NCT04849910 · Vor Biopharma FocusedView → | CD33+ acute myeloid leukemia or myelodysplastic syndromes | Phase 1/Phase 2 | Focused | View | |||
| ACCESS NCT04904588 · Center for International Blood and Marrow Transplant Research FocusedView → | hematologic malignancies | Phase 2 | Focused | View | |||
| MEDALIST NCT02631070 · Celgene FocusedView → | transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts | Phase 3 | Focused | View | |||
| NCT03802695 NCT03802695 · Orca Biosystems, Inc. FocusedView → | hematologic malignancies | Phase 1 | Focused | View | |||
| NCT04419649 NCT04419649 · Takeda FocusedView → | anemia in very low/low/intermediate risk myelodysplastic syndromes | Phase 2 | Focused | View | |||
| NCT04937166 NCT04937166 · Kahr Medical FocusedView → | AML, MDS and chronic myelomonocytic leukemia | Phase 1 | Focused | View | |||
| PyramIDH NCT06465953 · Institut de Recherches Internationales Servier FocusedView → | Not given | Phase 3 | Focused | View | |||